Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised Controlled Trial Evaluating a Novel Individualised Treatment Strategy for Carbapenem-Resistant Gram-Negative Bacteria Infections (iACT)

NCT04202861 is registered in ClinicalTrials.gov with Singapore General Hospital as lead sponsor.

NCT NCT04202861
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04202861 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised Controlled Trial Evaluating a Novel Individualised Treatment Strategy for Carbapenem-Resistant Gram-Negative Bacteria Infections (iACT)
Lead sponsor
Singapore General Hospital
Phase
Not applicable
Overall status
Unknown status
Start date
July 8, 2019
Completion date
March 31, 2023
Enrollment
594 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

antibiotic therapy